MAPT and early-onset autosomal dominant Alzheimer disease: We explore the impact of WZ4003 in both wildtype and APP/PS1 cultures, to assess whether NUAK1 inhibition has differential impacts on models of Aβ pathology, partially replicating changes seen in Alzheimer’s disease, where dysregulated Aβ processing is thought to drive downstream changes to tau [63].